AI182371 Activators
AI182371 Activators are a series of chemicals that enhance the functional activity of AI182371 through diverse mechanisms influencing intracellular signaling pathways. Forskolin, by increasing cAMP levels, activates PKA, which could directly phosphorylate AI182371 or alter the phosphorylation status of proteins that interact with AI182371, thereby enhancing its function. Similarly, PMA functions as a PKC activator and could heighten AI182371 activity by phosphorylating it or its associated proteins. Ionomycin and A23187 both raise intracellular calcium levels, activating calcium-dependent kinases that may target AI182371 for phosphorylation, thus promoting its functional activity. Isoproterenol, like Forskolin, increases cAMP and activates PKA, further potentiating AI182371 through similar cAMP-dependent pathways. IBMX and db-cAMP prevent cAMP degradationand mimic its effects, respectively, ensuring sustained PKA activation and subsequent enhancement of AI182371. EGCG indirectly contributes to the activity of AI182371 by inhibiting other kinases, potentially alleviating inhibitory phosphorylations that would otherwise dampen AI182371's activity.
LY294002 and PD98059, by inhibiting PI3K and MEK, alter the cellular signaling dynamics, potentially reducing negative feedback or cross-talk that suppresses AI182371's functional state, thereby indirectly promoting its activity. Sildenafil and Zaprinast, through their inhibition of phosphodiesterase-5, elevate cGMP levels, leading to PKG activation, which could then enhance AI182371 activity either directly or via interaction with other signaling proteins. Collectively, these AI182371 Activators, through targeted and indirect modulation of cellular signaling networks, elevate the activity of AI182371 without necessitating changes in its expression levels or direct activation, thereby serving as pivotal agents in promoting its functional state within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA acts as a PKC activator. PKC can phosphorylate AI182371 or associated substrates, leading to enhanced AI182371 activity through altered protein-protein interactions or modulation of its active site accessibility. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which can activate calcium-dependent protein kinases. These kinases may then directly or indirectly enhance AI182371 activity by phosphorylation or by changing the protein conformation to a more active state. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which prevents the breakdown of cAMP and cGMP, thereby sustaining their action. Elevated levels of cAMP/cGMP can lead to activation of PKA/PKG, which can enhance AI182371 activity through phosphorylation events. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that can decrease competitive signal transduction activities. This reduction can lead to an indirect enhancement of AI182371 activity by allowing more substrate availability or by preventing inhibitory phosphorylations. | ||||||
Calcium dibutyryladenosine cyclophosphate | 362-74-3 | sc-482205 | 25 mg | $147.00 | ||
db-cAMP is a cell-permeable cAMP analog that activates PKA. PKA activation can lead to enhanced AI182371 activity through direct phosphorylation or by creating a favorable environment for its activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can modulate downstream signaling pathways such as Akt. By inhibiting PI3K, the balance of cellular signaling can shift, potentially enhancing AI182371 activity by reducing negative regulatory effects exerted by the Akt pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that by blocking the MAPK/ERK pathway can lead to a compensatory upregulation of alternative pathways, which may include signaling routes that enhance AI182371 activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterases, particularly PDE5, leading to elevated cGMP levels. The resultant activation of PKG can enhance AI182371 activity by phosphorylation or by modulating the interaction with other proteins. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium concentrations, potentially enhancing AI182371 activity by activating calcium-dependent proteins that may phosphorylate or otherwise modify AI182371 to increase its activity. | ||||||